Theratechnologies announces publication in Frontiers in Immunology on TH1902

Theratechnologies announced the publication of a peer-reviewed article in Frontiers in Immunology that enhances understanding of the molecular mechanism of action of sudocetaxel zendusortide, known as TH1902, as a potential anticancer treatment. Sudocetaxel zendusortide is an investigational, first-in-class peptide-drug conjugate that targets the sortilin receptor and expedites the internalization and delivery of the cytotoxic payload directly into cancer cells. The article, “Sudocetaxel Zendusortide triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing” appears in the “Cancer Immunity and Immunotherapy” section of the February issue of the journal. It reports on preclinical research in which sudocetaxel zendusortide induced complete and prolonged tumor regression in a triple-negative breast cancer-derived xenograft tumor model and demonstrated tumor regression associated with growth inhibition and immune cell infiltration in a “cold” murine tumor model. Additionally, combining sudocetaxel zendusortide with an anti-PD-L1 checkpoint inhibitor led to increases in tumor growth inhibition and median animal survival.